Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioid Prescriber Training: US FDA Still Debating Mandate; CMS Policies Having Impact Now

25 May 2017

• By Michael McCaughan

Related Content

Opioids: FDA Eyes Better Prescriber Education, But Academics Urge Promotion Crackdown

20 Apr 2017

Opioid REMS: New CME 'Blueprint' To Include Immediate-Release Drugs

25 May 2017

Opioid Policy At US FDA To Become 'More Forceful,' Gottlieb Says

24 May 2017

Restrictive REMS Is Least Favored Path For Opioid Prescriber Education

09 May 2016

Additional Topics

United States FDA Regulation Drug Safety BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.